Turbine launches collaboration with AstraZeneca, leveraging Turbine’s virtual disease models to rationalize ADC discovery

CAR-T Digest - August 2020

09 October 2025: Turbine launches collaboration with AstraZeneca, leveraging Turbine’s virtual disease models to rationalize ADC discovery

Turbine and AstraZeneca have partnered to apply Turbine’s AI-driven virtual biology platform to accelerate antibody-drug conjugate (ADC) discovery by predicting response mechanisms and optimizing ADC positioning
The collaboration aims to reduce reliance on large-scale cell line and PDX screenings by using Turbine’s lab-in-the-loop approach, which selects key cell lines for testing and models thousands of in silico outcomes using AstraZeneca’s ADC datasets
This method enhances efficiency, speed, and mechanistic insight in ADC development, providing understanding of not just cell survival but also gene expression changes that drive sensitivity or resistance
The approach will help identify effective payloads and ADC combinations across diverse tumor types, improving clinical translatability and discovery precision
The partnership builds on previous Turbine–AstraZeneca collaborations using the Simulated Cell platform to study resistance mechanisms and combination synergies in cancer therapies